title: Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy.
abstract: BACKGROUND
  The use of biological therapy (biologicals) is established in the treatment of Crohn's disease. This study aimed to determine whether preoperative treatment with biologicals is associated with an increased rate of complications following surgery for Crohn's disease with intestinal anastomosis.
  
  
  METHODS
  All patients receiving biologicals and undergoing abdominal surgery with anastomosis or strictureplasty were identified at six tertiary referral centres. Demographic data, and preoperative, operative and postoperative details were registered. Patients who were treated with biologicals within 2 months before surgery were compared with a control group who were not. Postoperative complications were classified according to anastomotic, infectious or other complications, and graded according to the Clavien-Dindo classification.
  
  
  RESULTS
  Some 111 patients treated with biologicals within 2 months before surgery were compared with 187 patients in the control group. The groups were well matched. There were no differences between the treatment and control groups in the rate of complications of any type (34·2 versus 28·9 per cent respectively; P = 0·402), anastomotic complications (7·2 versus 8·0 per cent; P = 0·976) and non-anastomotic infectious complications (16·2 versus 13·9 per cent; P = 0·586). In univariable regression analysis, biologicals were not associated with an increased risk of any complication (odds ratio (OR) 1·33, 95 per cent confidence interval 0·81 to 2·20), anastomotic complication (OR 0·89, 0·37 to 2·17) or infectious complication (OR 1·09, 0·62 to 1·91).
  
  
  CONCLUSIONS
  Treatment with biologicals within 2 months of surgery for Crohn's disease with intestinal anastomosis was not associated with an increased risk of complications.
authors.affiliation: Division of Surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, and Department of Surgery, County Council of Östergötland, Linköping, Sweden; Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK.
authors.forename: P
authors.initials: P
authors.lastname: Myrelid
authors.forename: M
authors.initials: M
authors.lastname: Marti-Gallostra
authors.forename: S
authors.initials: S
authors.lastname: Ashraf
authors.forename: M L
authors.initials: ML
authors.lastname: Sunde
authors.forename: M
authors.initials: M
authors.lastname: Tholin
authors.forename: T
authors.initials: T
authors.lastname: Oresland
authors.forename: R E
authors.initials: RE
authors.lastname: Lovegrove
authors.forename: A
authors.initials: A
authors.lastname: Tøttrup
authors.forename: D W
authors.initials: DW
authors.lastname: Kjaer
authors.forename: B D
authors.initials: BD
authors.lastname: George
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D001688:Biological Products / Q000009:adverse effects*; D016022:Case-Control Studies; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology*; D011300:Preoperative Care / Q000009:adverse effects; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab